Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 16/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23296224 | 1.00 | YAP1 (0.75) | YAP1ALDH1A1TSHRKMT2AITGB3 | |
| SCHEMBL19982260 | 0.93 | YAP1 (0.82) | YAP1 | |
| SCHEMBL19982259 | 0.93 | YAP1 (0.82) | YAP1 | |
| SCHEMBL21358971 | 0.92 | YAP1 (0.74) | YAP1ITGB3ITGA2B | |
| SCHEMBL21366436 | 0.92 | YAP1 (0.74) | YAP1ITGB3ITGA2B | |
| SCHEMBL23296257 | 0.90 | YAP1 (0.82) | YAP1KMT2AITGB3ITGA2B | |
| SCHEMBL19974576 | 0.90 | YAP1 (0.82) | YAP1KMT2AITGB3ITGA2B | |
| SCHEMBL21359060 | 0.90 | YAP1 (0.75) | YAP1ALDH1A1TSHRKMT2A | |
| SCHEMBL21366291 | 0.90 | YAP1 (0.75) | YAP1ALDH1A1TSHRKMT2A | |
| SCHEMBL19974551 | 0.90 | YAP1 (0.69) | YAP1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3512839-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. Lee Moffitt Cancer Center And Research Institute, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018053446-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130297-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | YAP1 1/4885ALDH1A1 2858/4885TSHR 2903/4885 |
| US-11530182-B2 | YAP1 inhibitors that target the interaction of YAP1 with Oct4 | YAP1, YES1, MYC | YAP1 1/4885ALDH1A1 2858/4885TSHR 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.